Bayer one of the German most important companies engaged in the manufacture of products serving health care and nutrition areas. The share encounters an important barrier at the expense of the bullish trend.

Financial statements are not deteriorated but they lack of power to translate better sales into progress of the bottom lines. In addition, its P/E ratio is a bit over its peers at 21 times estimates while yields are pretty lower than them. On the other hand, debts are expected to emerge in current fiscal year to EUR 8.8 billion, thus an increase of 30% over prior year. Its EPS, downwardly revised by Thomson-Reuters analysts during the last 12 months shows a diminished reliance on the file for both 2014 and 2015.

Technically, the share seems to be integrated in a large accumulation phase, started back at the beginning of the year, as it evolves within the EUR 91.5/104 trading range. The EUR 104 daily resistance is a solid barrier capable to limit the rise of stock prices and could throw them back to the EUR 97.3 short term support.

Considering weakened financials and a reliable technical analysis, a short position could be taken close to EUR 104 in order to benefit from a further hollow toward the EUR 97.3. In case of further acceleration, the stop loss will be triggered around the EUR 105.